Effects of a new selective β 3 ‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease
LUTS: Lower Urinary Tract Symptoms · 2023
DOI: 10.1111/luts.12503 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2023. Verfasst von Mio Togo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal and Genitourinary Surgery, Graduate School of Medical Science, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objectives
Parkinson's disease caused by the loss of dopaminergic neurons induces not only motor dysfunction but also lower urinary tract dysfunction. Patients with Parkinson's disease have recently been reported to experience both urge urinary incontinence (overactive bladder) and stress urinary incontinence, the latter of which occurs when the pressure of the bladder exceeds that of the urethra. Vibegron is a highly selective novel β 3 ‐adrenoceptor agonist approved for the treatment of overactive bladder. However, how β 3 ‐adrenoceptor agonists affect urethral function remains unclear. In a clinical report, the urethral function of patients with Parkinson's disease was shown to be degraded. The present study aimed to investigate the effects of vibegron on lower urinary tract activity in a rat model of Parkinson's disease.
Methods
In a rat model of Parkinson's disease induced by unilateral 6‐hydroxydopamine injection into the substantia nigra pars compacta, we examined the effects of vibegron on bladder and urethral activity.
Results
Cystometric analysis revealed that, compared with vehicle injection, intravenous injection of 3 mg/kg vibegron significantly increased the inter‐contraction interval ( p < .05) and reduced voiding pressure ( p < .01). However, no significant effects on urethral function were observed.
Conclusions
The results of the present study provide corroborating evidence that bladder dysfunction is suppressed by the administration of vibegron in Parkinson's disease model rats, confirming that vibegron is effective for treating overactive bladder without further worsening urethral function. These findings may contribute to a better understanding of the mechanisms of β 3 ‐adrenoceptor agonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Renal and Genitourinary Surgery, Graduate School of Medical Science, Hokkaido University, Sapporo, Japan.
- Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
ORCID-Profile: Mio Togo, Takeya Kitta, Hiroki Chiba, Naohisa Kusakabe
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Togo, M., Kitta, T., Chiba, H., Higuchi, M., Kusakabe, N., Ouchi, M., Abe-Takahashi, Y., Kakizaki, H., & Shinohara, N. (2023). Effects of a new selective β 3 ‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12503
Vancouver
Togo M, Kitta T, Chiba H, Higuchi M, Kusakabe N, Ouchi M, et al. Effects of a new selective β 3 ‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease. LUTS: Lower Urinary Tract Symptoms. 2023. doi:10.1111/luts.12503
BibTeX
@article{Togo2023,
author = {Togo, Mio and Kitta, Takeya and Chiba, Hiroki and Higuchi, Madoka and Kusakabe, Naohisa and Ouchi, Mifuka and Abe-Takahashi, Yui and Kakizaki, Hidehiro and Shinohara, Nobuo},
title = {Effects of a new selective β 3 ‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2023},
doi = {10.1111/luts.12503}
}
EUVIMED